Royal Bank of Canada
TLOG

Royal Bank of Canada’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Royal Bank of Canada’s Portfolio TLOG Stock Details TLOG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-64
Closed – – 6271
2014
Q2 		$0 Buy
+64
New +$363 ﹤0.01% 6306

Other funds holding TLOG

CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
FWC
First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Royal Bank of Canada's TLOG Position: Q3 2014 in Review

Royal Bank of Canada sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q3 2014, closing a stake of 64 shares.

Royal Bank of Canada first reported a position in TLOG in Q2 2014 and held it in 1 quarter. The position peaked at $0 in Q2 2014. 25 funds tracked by Wall St. Rank hold TLOG as of Q3 2014.

  • Royal Bank of Canada reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q3 2014 after selling out during the quarter.
  • Royal Bank of Canada sold 64 TetraLogic Pharmaceuticals Corporation shares in Q3 2014.
  • Royal Bank of Canada first reported a position in TetraLogic Pharmaceuticals Corporation in Q2 2014 and held it in 1 quarter.
  • Royal Bank of Canada's TetraLogic Pharmaceuticals Corporation position peaked at $0 in Q2 2014.
  • 25 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q3 2014.

Based on Royal Bank of Canada's 13F filing for Q3 2014, filed 14 Nov 2014.